Related Experiment Video

Updated: May 27, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Role of Pioglitazone with Metformin or Glimepiride on Oxidative Stress-induced Nuclear Damage and Reproductive

Syed Imam Rabbani1, Kshama Devi, Salma Khanam

  • 1Department of Pharmacology, Al-Ameen College Of Pharmacy, Opp. Lalbagh Main Gate, Hosur Road, Bangalore-560027, India.

The Malaysian Journal of Medical Sciences : MJMS
|December 3, 2011
PubMed
Abstract

Insights

The combination of pioglitazone and metformin effectively reduced nuclear damage and sperm abnormalities in diabetic rats by improving antioxidant status. Pioglitazone with glimepiride showed no significant protective effects.

Area of Science:

  • Endocrinology
  • Toxicology
  • Pharmacology

Background:

  • Oxidative stress in diabetes contributes to secondary complications like cancer and birth defects.
  • Effective management of blood glucose is crucial for preventing diabetic complications.

Purpose of the Study:

  • To evaluate the protective effects of pioglitazone combined with metformin or glimepiride.
  • To assess the impact on nuclear damage and reproductive toxicity in a type-2 diabetes rat model.

Main Methods:

  • Rats were induced with type-2 diabetes using nicotinamide and streptozotocin.
  • Combinations of pioglitazone with metformin or glimepiride were administered orally for 4 weeks.
  • Evaluated micronuclei formation, sperm abnormalities, and antioxidant status (LPO, CAT, SOD).

Main Results:

  • Pioglitazone plus metformin significantly reduced micronucleated erythrocytes and sperm defects.
  • This combination also increased the P/N ratio and caudal sperm count.
  • Pioglitazone plus glimepiride did not show significant protective effects against nuclear or sperm damage.

Conclusions:

  • The pioglitazone-metformin combination demonstrates significant protective effects against nuclear damage and sperm abnormalities in diabetic rats.
  • These benefits are attributed to enhanced antioxidant status.
  • Pioglitazone-glimepiride combination was ineffective in mitigating these diabetic complications.
Keywords:
antidiabeticscombination therapyhealth sciencesmicronucleisperm abnormalities

More Related Videos

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals07:39

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals

Published on: June 25, 2018

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...